The FDA approved Abbott's CardioMEMS Hero reader on February 27, 2026, as a next-generation pulmonary artery (PA) pressure monitoring device for heart failure patients2
The Hero reader is 60% lighter and smaller than the previous CardioMEMS model, designed to fit in a carry-on suitcase for improved portability2
Patients take readings by laying with their back centered on the Hero reader for less than 60 seconds on average2
The device features integrated Wi-Fi and cellular connectivity, making it the only patient reader with this integrated capability2
The CardioMEMS HF System has demonstrated a 57% reduction in heart failure hospitalizations in clinical studies2
Approximately 6.7 million people in the United States currently have heart failure, with projections to reach 8.5 million by 20302
The Hero reader is compatible with the current commercially available version of the CardioMEMS PA Sensor, which is implanted during a minimally invasive outpatient procedure2
Abbott will soon begin commercial release of the CardioMEMS Hero reader in the United States2
Sources:
2. https://www.dicardiology.com/content/fda-grants-approval-abbots-cardiomems-hero-device